fleroxacin has been researched along with sulfamethoxazole in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hohl, P; Kafader, FM; Salfinger, M | 1 |
| Cullmann, W; Dechène, M; Stieglitz, M | 1 |
| Kearns, GL | 1 |
| M'imunya, JM; Mutua, FM; Wiysonge, CS | 1 |
2 review(s) available for fleroxacin and sulfamethoxazole
| Article | Year |
|---|---|
Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Topics: Bile; Biotransformation; Child; Child, Preschool; Cystic Fibrosis; Fleroxacin; Humans; Liver; Liver Circulation; Mixed Function Oxygenases; Pharmaceutical Preparations; Sulfamethoxazole; Theophylline | 1993 |
Genital ulcer disease treatment for reducing sexual acquisition of HIV.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chancroid; Female; Fleroxacin; HIV Infections; HIV Seronegativity; Humans; Male; Penicillin G Benzathine; Randomized Controlled Trials as Topic; Sulfamethoxazole; Syphilis; Trimethoprim | 2012 |
6 other study(ies) available for fleroxacin and sulfamethoxazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.
Topics: Amikacin; Anti-Bacterial Agents; Cefmenoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Drug Combinations; Fleroxacin; Mycobacterium; Nontuberculous Mycobacteria; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1987 |
[Comparative antibacterial activity of fleroxacin: selection frequencies and outer membrane proteins of resistant mutants].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Outer Membrane Proteins; Ciprofloxacin; Drug Combinations; Drug Resistance, Microbial; Escherichia coli; Fleroxacin; Humans; Mutation; Ofloxacin; Serratia marcescens; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |